tigecycline
| Form | Strength |
|---|---|
| POWDER FOR INJECTION, INTRAVENOUS | 50 mg |
| Per policy, use of these medications is restricted as noted below: | |
|---|---|
| generic (Brand) | Restrictions |
| tigecycline (Tygacil) | ID use only |
| Pediatric Pharmacy Association 2025 KIDs List of Key Potentially Inappropriate Drugs in Pediatrics | |
|---|---|
| Medication: | tigecycline (Tygacil) |
| Key Potentially Inappropriate Drugs in Pediatrics (KIDs) List: Second Edition (Table 1) | |
| Drug | tigecycline |
| Risk/Rationale | Retardation of skeletal development and bone growth |
| Recommendation | Caution in younger than 1 mo |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
| Drug | tigecycline |
| Risk/Rationale | Tooth discoloration |
| Recommendation | Caution in younger than 8 yr |
| Quality of evidence: High, Strength of Recommendation: Strong | |
| Drug | tigecycline |
| Risk/Rationale | Enamel hypoplasia |
| Recommendation | Caution in younger than 8 yr |
| Quality of evidence: High, Strength of Recommendation: Strong | |